Clinical Trial Update: Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax) [Phase 1]

View source ↗

Summary

Phase 1 pediatric study evaluating the immune response to the 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23) has completed, describing the dynamic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumococcal Pneumonia

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: KEMRI-Wellcome Trust Collaborative Research Program | Conditions: Pneumonia, Pneumococcal | Phase 1 | Status: COMPLETED